Compare Natera Inc. Common Stock (NTRA) vs RingCentral Inc. Class A Common Stock (RNG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Natera Inc. Common Stock vs RingCentral Inc. Class A Common Stock — how do they compare? Natera Inc. Common Stock trades at $392.78 (market cap $57.03B), while RingCentral Inc. Class A Common Stock trades at $74.8 (market cap $6.28B). The key difference: Natera Inc. Common Stock is far larger — about 9.1× RingCentral Inc. Class A Common Stock's market cap, and RingCentral Inc. Class A Common Stock pays a 0.37% dividend while Natera Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Natera Inc. Common Stock for 0 Days and RingCentral Inc. Class A Common Stock for 6 Days on average.
| NTRA | RNG | |
|---|---|---|
Market Cap | $57.03B | $6.28B |
Volume | 1,131,157 | 1,803,900 |
Sector | Health | Technology |
52-Week High | $425.64 | $79.82 |
52-Week Low | $179.42 | $24.82 |
Typical Hold Time | 0 Days | 6 Days |
Enterprise Value | $56.18B | $7.33B |
Dividend Yield | — | 0.37% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
NTRA trades at $395.66, down 0.53% today but remains near recent highs. The stock shows mixed technical signals with neutral momentum indicators. Fundamentally, the company demonstrates strong revenue growth ($2.31B in 2025, projected $2.7B in 2026) but continues to operate at a net loss (-$208M in 2025). Recent positive developments include FDA Breakthrough Device designation for its multi-cancer detection assay and regulatory approval in Japan for Signatera.
NTRA presents a growth story with significant analyst support (89% buy ratings) but carries execution risks. The stock trades at premium valuations (P/S 20.48) while still unprofitable. Key catalysts include clinical trial progress and international expansion, though investors face risks from ongoing losses and competitive pressures in precision medicine.
RingCentral (RNG) trades at $78.69, up 0.67% on the day and near its 52-week high, reflecting strong momentum. The stock is technically bullish with moving averages supporting the uptrend. Fundamentally, the company shows revenue growth to $2.52 billion in 2025, with net income of $43.39 million and improving margins. Recent earnings beats and strategic AI partnerships, like the one with Allnet.Italia announced October 13, 2026, underscore growth potential. Analyst sentiment is overwhelmingly positive with 28 buy ratings and a consensus price target of $61.00, though the current price exceeds this target.
The outlook for RNG is favorable driven by AI integration and earnings momentum, but risks include high valuation with a P/E of 62.54 and potential volatility ahead of Q3 2026 results on October 22, 2026. Investor focus remains on execution and margin expansion amid competitive pressures.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Natera Inc. Common Stock
Natera, Inc. develops and provides cell-free DNA-based genetic testing across women's health, oncology, organ health, and rare disease, with flagship products including Panorama for noninvasive prenatal screening and Signatera for cancer recurrence monitoring.
Read more on NTRA →About RingCentral Inc. Class A Common Stock
RingCentral provides cloud-based business communications and contact center solutions. Its platform combines phone, messaging, video meetings, and customer-service tools.
Read more on RNG →
